Skip to main content
Equibles
PVLA logo

PVLA · Palvella Therapeutics, Inc.

Track PVLA — free

Use PVLA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$149.97 -0.36 (-0.24%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$2.18B
Shares
14.41M

Palvella Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Palvella Therapeutics, Inc. (PVLA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼80.6% $2.94M −$14.28M '20 Q3 20-11-04 ▼89.1% $1.88M −$14.40M '20 Q4 21-03-30 ▲17.9% $15.63M −$4.17M '21 Q1 21-05-17 ▼70.8% $3.29M −$15.50M '21 Q2 21-08-04 ▲38% $4.06M −$16.54M '21 Q3 21-11-02 ▼29.7% $10.99M −$5.10M '22 Q1 22-05-11 ▲12.6% $3.70M −$10.34M '22 Q2 22-08-04 ▲32.4% $5.37M −$9.74M '22 Q3 22-11-02 LATEST ▼30.8% $5.85M −$8.10M '22 Q4 23-03-29
Conference
Investor event
2026-08-12
Palvella Therapeutics, Inc. (PVLA) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Confident tone Cutorin rapamycin and pipeline expansion NDA progress and FDA approval timeline Regulatory designations (breakthrough/fast-track/orphan)
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Palvella Therapeutics, Inc. (PVLA) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Confident tone Phase 3 SELVA results and NDA progress Pipeline expansion beyond lead indication U.S. commercial launch readiness
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Palvella Therapeutics, Inc. (PVLA) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-11
Palvella Therapeutics, Inc. (PVLA) Q3 2025 Earnings Call
Diluted EPS
$-1.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Palvella Therapeutics, Inc. (PVLA) Q2 2025 Earnings Call
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Palvella Therapeutics, Inc. (PVLA) Q1 2025 Earnings Call
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Palvella Therapeutics, Inc. (PVLA) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q4
2023-03-29
Palvella Therapeutics, Inc. (PVLA) Q4 2022 Earnings Call
Revenue
$5.85M*
▼ 30.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Palvella Therapeutics, Inc. (PVLA) Q3 2022 Earnings Call
Revenue
$5.37M
▲ 32.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2022 Earnings Call
Revenue
$3.70M
▲ 12.6% YoY
Diluted EPS
$-11.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Palvella Therapeutics, Inc. (PVLA) Q1 2022 Earnings Call
Revenue
$10.99M
▼ 29.7% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-02
Palvella Therapeutics, Inc. (PVLA) Q3 2021 Earnings Call
Revenue
$4.06M
▲ 38% YoY
Diluted EPS
$-19.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2021 Earnings Call
Revenue
$3.29M
▼ 70.8% YoY
Diluted EPS
$-20.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Palvella Therapeutics, Inc. (PVLA) Q1 2021 Earnings Call
Revenue
$15.63M
▲ 17.9% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
Palvella Therapeutics, Inc. (PVLA) Q4 2020 Earnings Call
Revenue
$1.88M*
▼ 89.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Palvella Therapeutics, Inc. (PVLA) Q3 2020 Earnings Call
Revenue
$2.94M
▼ 80.6% YoY
Diluted EPS
$-20.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Palvella Therapeutics, Inc. (PVLA) Q2 2020 Earnings Call
Revenue
$11.25M
▲ 110.9% YoY
Diluted EPS
$-7.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Palvella Therapeutics, Inc. (PVLA) Q1 2020 Earnings Call
Revenue
$13.26M
▲ 55.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Palvella Therapeutics, Inc. (PVLA) Q4 2019 Earnings Call
Revenue
$17.27M*
▲ 251.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–21 of 21 earnings calls
Key facts CIK 1583648 CUSIP 697947109 13F (30d) 175 filings 172 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)